Tirzepatide vs Semaglutide:
Which Weight Loss Medication Is Right for Men?

Two years ago, semaglutide (Ozempic/Wegovy) was the clear frontrunner in medical weight loss. Then came tirzepatide (Mounjaro/Zepbound) — and the conversation changed. Tirzepatide consistently outperforms semaglutide in head-to-head data, producing greater weight loss with a comparable side effect profile. But "better on average" doesn't mean "right for every man." Here's an honest clinical comparison so you can have an informed conversation with your physician.

GLP-1 vs. Dual GLP-1/GIP: Understanding the Mechanism

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It signals fullness to the brain, slows gastric emptying, stimulates insulin secretion, and suppresses glucagon. Semaglutide mimics this signal powerfully — far beyond what your gut produces naturally.

Tirzepatide is a dual agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is another incretin hormone that plays a distinct role in fat storage, adipose tissue metabolism, and insulin sensitivity. The dual mechanism appears to be more than additive — tirzepatide produces weight loss results that exceed what GLP-1 agonism alone can achieve.

Both medications are once-weekly subcutaneous injections. Both require gradual dose escalation to minimize side effects. The administration experience is essentially identical.

SURMOUNT Trial Results: What the Numbers Actually Show

The SURMOUNT-1 trial — tirzepatide's landmark obesity study — enrolled over 2,500 adults with obesity (BMI ≥30) or overweight with at least one weight-related condition. Results at 72 weeks were striking:

• 5 mg tirzepatide: Average body weight reduction of 15.0%
• 10 mg tirzepatide: Average body weight reduction of 19.5%
• 15 mg tirzepatide: Average body weight reduction of 20.9%
• Placebo: 3.1% weight reduction

Critically, 57% of participants on the highest tirzepatide dose lost 20% or more of their body weight. For semaglutide's comparable STEP-1 trial, the average weight loss was 14.9% — impressive, but meaningfully lower than tirzepatide's top doses.

For a 240-pound man, tirzepatide at maximum dose projects to roughly 50 pounds of weight loss over 72 weeks. Semaglutide projects to approximately 36 pounds over a similar timeframe. That's a meaningful clinical difference.

Head-to-Head: The SURMOUNT-5 Data

SURMOUNT-5, published in late 2024, provided the first direct randomized comparison of tirzepatide versus semaglutide for weight loss. Both medications were titrated to maximum tolerated doses. Results showed tirzepatide produced approximately 47% greater weight loss than semaglutide over 72 weeks (20.2% vs 13.7% body weight reduction).

Importantly, both medications showed similar rates of discontinuation due to adverse events — primarily gastrointestinal side effects. Tirzepatide's superior efficacy did not come at the cost of worse tolerability, which was a concern some clinicians had hypothesized.

Side Effect Profiles: What to Expect With Each

The side effect profiles of semaglutide and tirzepatide are broadly similar, reflecting their shared GLP-1 mechanism. The most common issues are gastrointestinal, particularly during dose escalation:

• Nausea: Most common with both; typically peaks at 1–2 weeks after each dose increase
• Constipation: More commonly reported with semaglutide; tirzepatide users report slightly more diarrhea
• Vomiting: Less common with slow titration; present with both medications
• Fatigue: Transient, typically resolves as dose stabilizes
• Injection site reactions: Mild, self-limiting with both

Both medications carry the same black box warning regarding medullary thyroid cancer risk (based on animal data) and are contraindicated with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2. Pancreatitis is a rare but reported serious adverse event with both.

Who Is a Candidate, and Who Should Choose Which?

Both medications are FDA-approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, etc.). The clinical decision between them involves several practical factors:

• Choose tirzepatide if: You have significant weight to lose (40+ lbs), also have type 2 diabetes or insulin resistance, or want maximum efficacy
• Choose semaglutide if: Insurance covers semaglutide but not tirzepatide, you have strong GI sensitivity, or you're a candidate for the cardiovascular benefit indication (semaglutide/Wegovy has FDA approval for CV risk reduction)
• Insurance coverage often drives the decision — coverage varies substantially by carrier and plan; your physician can navigate prior authorization for either

Combining Either Medication With TRT

Both tirzepatide and semaglutide pair well with testosterone replacement therapy for men with low T. The mechanism is the same: GLP-1 medications drive fat loss, which reduces aromatase activity and lowers estrogen production. This can actually raise endogenous testosterone in men who aren't yet on TRT — and for men already on TRT, fat loss improves body composition and hormonal efficiency.

The critical advantage of combining either GLP-1 medication with TRT is muscle preservation. Rapid weight loss without hormonal support causes significant lean mass loss — as much as 25–40% of total weight lost can come from muscle. Testosterone is a powerful anti-catabolic signal that helps ensure you're losing fat, not muscle, during caloric restriction.

Insurance Coverage and Cost Reality

This is where many men hit a wall. Both tirzepatide (Zepbound) and semaglutide (Wegovy) for weight loss have inconsistent insurance coverage, as most commercial plans have historically excluded "weight loss drugs." This is changing, but slowly.

If you have type 2 diabetes, coverage is far better — Mounjaro (tirzepatide for diabetes) and Ozempic (semaglutide for diabetes) are widely covered. For the obesity indication, your physician will help determine what your specific plan covers and navigate prior authorization if needed. Manufacturer savings programs can significantly reduce out-of-pocket costs for commercially insured patients.

Our Recommendation

If efficacy is your primary goal and insurance or cost is not a barrier, tirzepatide is now our first-line recommendation for medical weight loss in men without contraindications. The SURMOUNT-5 data makes a compelling case for its superiority. That said, both medications are remarkably effective compared to anything available even five years ago — and semaglutide remains an excellent option in the right clinical situation. A physician evaluation is the only way to determine what's appropriate for you.